CN114761433A - 一种抗Claudin18.2单克隆抗体、其制备方法及用途 - Google Patents

一种抗Claudin18.2单克隆抗体、其制备方法及用途 Download PDF

Info

Publication number
CN114761433A
CN114761433A CN202080085731.4A CN202080085731A CN114761433A CN 114761433 A CN114761433 A CN 114761433A CN 202080085731 A CN202080085731 A CN 202080085731A CN 114761433 A CN114761433 A CN 114761433A
Authority
CN
China
Prior art keywords
seq
monoclonal antibody
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080085731.4A
Other languages
English (en)
Inventor
洪雪娇
刘俊利
何虹霖
李超群
许旭
姜伟东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fuhong Hanlin Biomedical Co ltd
Shanghai Fuhong Hanlin Biopharmacy Co ltd
Shanghai Henlius Biotech Inc
Original Assignee
Shanghai Fuhong Hanlin Biomedical Co ltd
Shanghai Fuhong Hanlin Biopharmacy Co ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fuhong Hanlin Biomedical Co ltd, Shanghai Fuhong Hanlin Biopharmacy Co ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Fuhong Hanlin Biomedical Co ltd
Publication of CN114761433A publication Critical patent/CN114761433A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种抗Claudin18.2单克隆抗体及其用途。编码该抗体的核酸分子，表达该抗体的表达载体、宿主细胞，以及含有该抗体的药物组合物。该抗体单独或与抗Her2抗体和/或IL15等其他药剂联合用于制备抗癌药物的用途。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202080085731.4A 2019-12-11 2020-12-09 一种抗Claudin18.2单克隆抗体、其制备方法及用途 Pending CN114761433A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911266831 2019-12-11
CN2019112668312 2019-12-11
PCT/CN2020/134775 WO2021115303A1 (zh) 2019-12-11 2020-12-09 一种抗Claudin18.2单克隆抗体、其制备方法及用途

Publications (1)

Publication Number Publication Date
CN114761433A true CN114761433A (zh) 2022-07-15

Family

ID=76328848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080085731.4A Pending CN114761433A (zh) 2019-12-11 2020-12-09 一种抗Claudin18.2单克隆抗体、其制备方法及用途

Country Status (2)

Country Link
CN (1) CN114761433A (zh)
WO (1) WO2021115303A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116253800A (zh) * 2022-11-30 2023-06-13 华道(上海)生物医药有限公司 一种抗cldn18.2的重链抗体、相关产品和用途
WO2024067759A1 (zh) * 2022-09-29 2024-04-04 北京诺诚健华医药科技有限公司 一种能够结合cldn18.2的抗体或其抗原结合片段及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813779B (zh) * 2023-06-28 2023-12-15 杭州斯达特生物科技有限公司 一种抗Claudin18.2重组单克隆抗体及其制备与应用
CN116903745B (zh) * 2023-09-13 2023-11-14 苏州仁端生物医药科技有限公司 一种抗人Claudin18.2的单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
SG10202111141WA (en) * 2018-05-18 2021-11-29 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067759A1 (zh) * 2022-09-29 2024-04-04 北京诺诚健华医药科技有限公司 一种能够结合cldn18.2的抗体或其抗原结合片段及其应用
CN116253800A (zh) * 2022-11-30 2023-06-13 华道(上海)生物医药有限公司 一种抗cldn18.2的重链抗体、相关产品和用途
CN116253800B (zh) * 2022-11-30 2024-04-12 华道(上海)生物医药有限公司 一种抗cldn18.2的重链抗体、相关产品和用途

Also Published As

Publication number Publication date
WO2021115303A1 (zh) 2021-06-17

Similar Documents

Publication Publication Date Title
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
CN112399974B (zh) 与人Claudin 18.2结合的抗体及其用途
CN110050000B (zh) 含有TGF-β受体的融合蛋白及其医药用途
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
EP3922647A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN109053892B (zh) 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
TW201141519A (en) Anti-HER2 antibodies and compositions
CN111094339B (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
EP4043495A1 (en) Anti-human trop-2 antibody and application thereof
TW200829602A (en) Novel antiproliferation antibodies
JP2023179450A (ja) 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途
EP4359083A1 (en) Antibodies against egfr and their uses
CN115038497A (zh) TGF-β-RII结合蛋白质
EP4180457A1 (en) Anti-cldn-18.2 antibody and use thereof
US20230374132A1 (en) Anti-cd3 antibody and uses thereof
WO2021013061A1 (zh) 一种人源化抗vegfr2抗体及其应用
CN116102649A (zh) 抗cldn18.2单克隆抗体及其应用
KR20230005281A (ko) Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
WO2023172981A1 (en) Antibodies against egfr and their uses
CN116925222A (zh) 抗pvrig抗体、其药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078463

Country of ref document: HK